An editorial reading of the regulatory record

What this site is

CJC-1295 Legal is an independent editorial project that publishes summaries of the peer-reviewed research literature, the FDA briefing documents, the WADA Prohibited List, the NCAA banned-substance class, the Department of Defense supplement policy, and the underlying U.S. statutes that touch the long-acting GHRH analog CJC-1295. Our work is editorial commentary on publicly available science and publicly filed regulatory documents.

The site reads as a regulatory explainer rather than as a sales surface because the topic — what U.S. federal, anti-doping, and state regulatory law actually says about a compound that has never been approved for any human indication — is genuinely complicated and is widely misreported in popular and industry coverage. The two specific misreadings we work hardest to correct are (1) the claim that 21 U.S.C. § 333(e) — the human growth hormone criminal statute — clearly reaches GHRH analogs on its face, and (2) the claim that a research use only label on its own immunizes a product whose objective intended use is human administration. The first is contested in the commentary; the second is rejected outright by FDA under its intended-use doctrine.

What this site is not

Not a law firm. We do not provide legal advice. Nothing on this site creates an attorney-client relationship. If you have a specific legal question about your jurisdiction, your facility, your athletic eligibility, your immigration status, or your specific situation, talk to a lawyer admitted in your jurisdiction. Editorial framing in the domain name — the word Legal — is a position the publisher occupies relative to the underlying body of law, not a claim about the site's services.

Not a clinic. We do not employ clinicians or pharmacists, we do not prescribe, we do not diagnose, we do not refer, and we do not provide medical advice. There is no our doctors, no our clinical team, and no our pharmacists here. The site does not have a clinic affiliation, a physical address, or a telephone line answered by a healthcare worker.

Not a vendor. We do not manufacture, sell, distribute, market, recommend, or refer any product. We have no commercial relationship with any peptide supplier, compounding pharmacy, telehealth platform, anti-aging clinic, or research-chemical company. We do not run an affiliate program and we do not earn referral fees from any vendor or laboratory. There are no product links on this site for the simple reason that the site is not in the business of moving any product.

Editorial standards and sourcing

Every quantitative claim on every page is attributed to a primary source — a peer-reviewed paper, an FDA briefing document, a WADA publication, a U.S. Code provision, or (in a small number of cases) a legal-industry analysis where it offers a useful synthesis. Inline citations as [N] correspond to numeric IDs in the reference index on /references. Where a citation is paywalled, the linked surface is the most authoritative open-access version available (PubMed abstract, FDA docket page, Cornell Legal Information Institute statute text).

The site does not invent research. If a claim is not supported by a primary source in the reference index, it does not appear on the site. The editorial register is plain English and deliberately avoids both the legalistic hedging of a formal opinion letter and the hyperbolic anti-use prose that often colors peptide coverage in industry trade press — the goal is a clear, attributed reading of the law as it sits, not advocacy in either direction.

When a citation is updated — when WADA publishes a new annual Prohibited List, when FDA issues a new Warning Letter campaign, when PCAC takes additional action — the entry is revised in place. The version-dated nature of the regulatory record is one of the structural features the site is built to respect.